Format

Send to

Choose Destination
Intern Med. 2017 Sep 1;56(17):2325-2328. doi: 10.2169/internalmedicine.8467-16. Epub 2017 Aug 10.

Interstitial Lung Disease Induced by Osimertinib for Epidermal Growth Factor Receptor (EGFR) T790M-positive Non-small Cell Lung Cancer.

Author information

1
Department of Respiratory Medicine, Graduate School of Medicine, Osaka City University, Japan.
2
Department of Clinical Oncology, Graduate School of Medicine, Osaka City University, Japan.
3
Department of Premier Preventive Medicine, Graduate School of Medicine, Osaka City University, Japan.
4
Department of Pathology, Graduate School of Medicine, Osaka City University, Japan.

Abstract

A 75-year-old man with stage IV lung adenocarcinoma was treated with osimertinib due to disease progression despite having been administered erlotinib. Both an epidermal growth factor receptor (EGFR) L858R mutation on exon 21 and a T790M mutation on exon 20 were detected in a specimen from a recurrent primary tumor. Five weeks after osimertinib initiation, he developed general fatigue and dyspnea. Chest computed tomography scan revealed diffuse ground glass opacities and consolidation on both lungs. An analysis of the bronchoalveolar lavage fluid revealed marked lymphocytosis, and a transbronchial lung biopsy specimen showed a thickened interstitium with fibrosis and prominent lymphocytic infiltration. We diagnosed the patient to have interstitial lung disease induced by osimertinib.

KEYWORDS:

T790M resistance mutation; epidermal growth factor receptor; interstitial lung disease; non-small cell lung cancer; osimertinib; transbronchial lung biopsy

PMID:
28794368
PMCID:
PMC5635308
DOI:
10.2169/internalmedicine.8467-16
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for J-STAGE, Japan Science and Technology Information Aggregator, Electronic Icon for PubMed Central
Loading ...
Support Center